Evaluation of an isotonic tear in combination with topical cyclosporine for the treatment of ocular surface disease.

PURPOSE: To determine whether a new category of artificial tear product, carboxymethylcellulose 0.5% with compatible solutes (CMC-solutes) (Optive, Allergan, Inc., Irvine, California) improves clinical outcomes when used adjunctively with topical cyclosporine 0.05% (Restasis, Allergan, Inc., Irvine, California) for the treatment of ocular surface disease. METHODS: Nineteen patients with ocular surface disease treated with cyclosporine 0.05% for at least 3 months and who had previously used other artificial tears adjunctively were enrolled. Patients discontinued their previous artificial tear and used CMC-solutes, concomitant with topical cyclosporine 0.05%. Corneal evaluation and tear production parameters were evaluated before and during combined CMC-solutes/cyclosporine treatment. Patients also completed a questionnaire before and during treatment with combined CMC-solutes/cyclosporine. Follow-up was at 1 and 3 months. RESULTS: Most objective measures of ocular surface health were unchanged, but an improvement in conjunctival lissamine green staining and tear break-up time was found. Conjunctival lissamine green staining scores improved from 3.4 +/- 2.5 to 1.9 +/- 2.5 by Month 3 (p = 0.004). Tear break-up time improved from 4.6 +/- 3.9 s pre-treatment to 5.3 +/- 3.8 s post-treatment (p = 0.049). Ocular Surface Disease Index (OSDI) scores improved from 16.2 +/- 9.4 at baseline to 11.5 +/- 8.9 at month 3 (p = 0.007). Subjectively, patients graded their ocular discomfort as 2.7 at baseline and as 2.3 at Month 3 (p = 0.049). At Month 3, 89.5% of patients said they liked CMC-solutes as well or better than previous drops they had used. All patients said CMC-solutes provided similar or improved relief of symptoms of dry eye than previous eye drops. There were no tear-related adverse events reported. CONCLUSIONS: In this study, CMC-solutes, when used in conjunction with cyclosporine 0.05%, provided patients with an improvement in objective signs and subjective symptoms of ocular surface disease compared to their previous artificial tears. Further studies are warranted.

Use of the artificial iris implant in patients with aniridia.

BACKGROUND: Aniridia (or partial aniridia) often occurs as a result of a penetrating ocular trauma. This condition may cause symptoms including glare, light sensitivity, reduced vision, and asymmetric appearance. Options for these patients include specialty contact lenses, corneal tattooing, and artificial iris implants. This article details six patients who experienced penetrating trauma with significant iris tissue loss and who chose to have an artificial iris implant. CASE REPORTS: Six patients with traumatic aniridia were enrolled in a single-site, single-surgeon study. They were followed for one year postoperatively. All six were complex cases that had multiple eye problems, such as aphakia, corneal scarring, corneal graft rejection, and retinal detachment. All participants were male. All patients experienced decrease in glare and light sensitivity following artificial iris implant surgery. Two experienced improved best-corrected vision (BCVA). All six patients felt the cosmetic appearance of their affected eye improved. CONCLUSIONS: The artificial iris device provides an effective means of treating traumatic aniridia. Optometrists often work with patients who have experienced a penetrating ocular trauma, with complete or partial aniridia as a complication. In cases in which nonsurgical means are not effective in returning the patient to comfort and productivity, an artificial iris implant should be considered.